Par Mahadevia MD

One thing I know for sure. Plays like this will absolutely win the hearts of Sooner Nation. The dude has guts #OUDNA

So excited to share the #COCOON study met its primary endpoint. Thank you @jillfeldman4 & thank you to all the investigators and most importantly the patients who made this study possible. To my @JNJInnovMed team, you were amazing! #My Company innovativemedicine.jnj.com/newsroom/cocoo…

@JoshuaBRobbins What are the specific development priorities for Sarr defensively?

Hey there, everybody! What questions do you have about the Washington Wizards? Please drop your question as a reply to this note, and I'll answer in an upcoming mailbag or here on Twitter.

RYBREVANT® marketing application submitted to European Medicines Agency based on PALOMA-3 study. #MyCompany prnewswire.com/news-releases/…

With my amazing lung cancer oncology global medical affairs @JNJInnovMed team here at #ASCO24, including @JuIianKam who just joined the team! #MyCompany

The #OncoAlertTopTweet 🚨Day 1 #ASCO24 by @DrSanjayPopat Subgroup analysis in MARIPOSA1: consistent benefit in all subgroups #OncoAlertAF @nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1 @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @dr_yakupergun @to_be_elizabeth @anmwongNZ @lungoncdoc

My colleague Helena Yu presented @MSK_DeptOfMed @MSKCancerCenter investigator-initiated clinical trial of amivantamab + lazertinib in patients with EGFR mutations AND brain mets Or leptomeningeal disease. Enrolled 42 patients in 24 months #ASCO24 #lcsm

Love the butterfly theme here at #ELCC24 . Very much a favorite of mine! #MyCompany

Congratulations to the dynamic duo @DanSteinfort and @_ShankarSiva on publication of the SEISMIC study showing the importance of systematic mediastinal node sampling in patients with early stage and locally advanced NSCLC @LancetRespirMed 👏🏽👏🏽

@deeptibehl1 Happy Diwali!

Wishing everyone a very happy Diwali! May the coming year bring peace and joy to all. 🪔🪔II सर्वे भवन्तु सुखिन:II 🪔🪔

@AngelQinMD Congrats Angel!

For US #HCPs: the Phase 2 COCOON study (NCT06120140) in patients with locally advanced or metastatic EGFR-mutated non-small cell #LungCancer is now on clinicaltrials.gov/study/NCT06120….

Excited to be leading a 2-day symposium here @JNJInnovMed within our incredible organization. As scientists and researchers we will be sharing and discussing the amazing research in Oncology we are leading but also how we continue to innovate in improve care! #MyCompany

@HosseinBorghaei @StephenVLiu @myESMO Ha ha ha, too good!

Tweeting THE tweeter! ⁦@StephenVLiu⁩. #ESMO23 ⁦@myESMO⁩

ESMO presidential plenary-exciting data on lung, breast and prostate cancer. #ESMO2023 #MyCompany

Presidential #ESMO23 speakers! #Mariposa and #Mariposa2 butterflies @APassaroMD and Dr Cho! Time to fly. #NSCLC #EGFR #MyCompany

Presented at #ESMO23: The addition of amivantamab to chemotherapy in patients with advanced non–small-cell lung cancer with EGFR exon 20 insertions resulted in significantly longer progression-free survival. Full results of the phase 3 PAPILLON trial: nej.md/3rYHf7e

For US #HCPs at #ESMO23: see Dr. Nicolas Girard (@nicogirardcurie) present primary results from the Phase 3 PAPILLON study in patients with EGFR exon 20 insertion-mutated advanced non-small cell #LungCancer.

Excited to be at ESMO. Saturday Presidential Plenary starting. PAPILLON Phase 3 study of amivantamab-chemotherapy vs. chemotherapy in 1L EGFR Exon-20 Insertion Advanced NSCLC will be presented. Simultaneous publication at New England Journal of Medicine #ESMO #MyCompany

#WCLC21 Amivantamab in METex14 NSCLC with RR 64% (5 confirmed, 4 not yet confirmed) including activity post #MET TKI therapy. Time to response 4.1 months. Interesting that one response occurred late on the spider plot. 11/14 still on therapy.